APTO News and Press, Aptose Biosciences Inc.

Century Therapeutics Inc. (IPSC) is expected to report $-0.38 for Q2 2025 Birchtech Corp Com (BCHT) is expected to report for Q2 2025 Cellectar Biosciences Inc. (CLRB) is expected to report $-3.6 for Q2 2025 Acuren Corporation (TIC) is expected to report for quarter end 2025-06-30 ...

Aptose Biosciences Inc. (APTO) is expected to report for Q2 2025

urban-gro Inc. (UGRO) is expected to report for quarter end 2025-03-31 Karman Holdings Inc. (KRMN) is expected to report $0.02 for Q1 2025 PyroGenesis Inc Com (PYRGF) is expected to report for quarter end 2025-03-31 GeoVax Labs Inc. (GOVX) is expected to report $-0.59 for Q1 2025 ...

Aptose is developing TUS+VEN+AZA as a one-of-a-kind safe and mutation agnostic frontline triple drug therapy for newly diagnosed AML patients First two dose cohorts of TUS+VEN+AZA triplet demonstrate safety, complete remissions, and MRD negativity across patients with diverse mutations, i...

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnosed...

SAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with newly diagnose...

2025-04-01 08:46:03 ET More on Aptose Biosciences Aptose Biosciences GAAP EPS of -$36.38 Aptose Biosciences approves 1-for-30 reverse share split to restore Nasdaq compliance Seeking Alpha’s Quant Rating on Aptose Biosciences Historical earnings data f...

SAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug frontline therapy to treat patients with n...

2025-03-28 08:17:26 ET More on Aptose Biosciences Aptose Biosciences approves 1-for-30 reverse share split to restore Nasdaq compliance Aptose Biosciences announces resale of 12.03M shares by Keystone Capital Partners Seeking Alpha’s Quant Rating on Aptose Bio...

Tuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion Agreement with Hanmi SAN DIEGO and TORONTO, March 28, 2025 (GLOBE NEWSWI...